Exercise for Patients With Renal Cell Cancer Receiving Sunitinib

NCT00869011

Last updated date
Study Location
Section Sports Medicine, Charité Universitätsmedizin Berlin, Hindenburgdamm 30
Berlin, , 12200, Germany
Contact
+493084452098

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

+493084452098

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- 18 to 75 years

- Understanding of written German

- Treatment with Sunitinib

- Ability to walk

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by
exercise


- BMI < 18 or > 30

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Renal Cell CarcinomaAxitinib Therapy Management Study
NCT04555603
  1. New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal Cell CarcinomaA Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
NCT00480935
  1. Toronto, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal Cell CarcinomaBevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma
NCT00556205
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal Cell CarcinomaA Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma
NCT00788060
  1. Durham, North Carolina
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Exercise for Patients With Renal Cell Cancer Receiving Sunitinib
Official Title  ICMJE Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib)
Brief Summary In this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, rest blood pressure and hear function) and the fatigue and mood of patients with renal cell carcinoma undergoing a therapy with Sunitinib.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Supportive Care
Condition  ICMJE Renal Cell Carcinoma
Intervention  ICMJE Other: Endurance exercise
Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
Study Arms  ICMJE
  • Experimental: 1
    Exercise
    Intervention: Other: Endurance exercise
  • No Intervention: 2
    No structured exercise program
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: March 24, 2009)
70
Original Estimated Enrollment  ICMJE Same as current
Study Completion Date  ICMJE Not Provided
Estimated Primary Completion Date June 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • 18 to 75 years
  • Understanding of written German
  • Treatment with Sunitinib
  • Ability to walk

Exclusion Criteria:

  • Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by exercise
  • BMI < 18 or > 30
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00869011
Other Study ID Numbers  ICMJE SUIR8687
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party PD Dr. Fernando C. Dimeo, Dept. of Sports Medicine, Charité Universitätsmedizin Berlin
Study Sponsor  ICMJE Charite University, Berlin, Germany
Collaborators  ICMJE Pfizer
Investigators  ICMJE Not Provided
PRS Account Charite University, Berlin, Germany
Verification Date December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP